Ascentage Pharma to Present at Three Key Oncology Investor Conferences
Event summary
- Ascentage Pharma will participate in three investor conferences in May and June 2026, including B. Riley's Commercial/Late-Stage Oncology Best Ideas Summit, Stifel's Virtual Targeted Oncology Forum, and Jefferies Global Healthcare Conference.
- The company will host one-on-one meetings and a fireside chat on May 19th at 10:30 am EDT, followed by a presentation on June 3rd at 8:10 am EDT.
- Ascentage Pharma's pipeline includes Olverembatinib, approved in China for CML treatment, and Lisaftoclax, a novel Bcl-2 inhibitor for hematologic malignancies.
- The company is conducting multiple global Phase III trials, including POLARIS-2 for CML, POLARIS-1 for Ph+ ALL, and POLARIS-3 for SDH-deficient GIST patients.
- Ascentage Pharma has partnerships with leading biotech and pharmaceutical companies, including Takeda, AstraZeneca, Merck, Pfizer, and Innovent.
The big picture
Ascentage Pharma's participation in multiple high-profile investor conferences underscores its strategic focus on expanding investor awareness and securing partnerships for its oncology pipeline. The company's ongoing Phase III trials and existing approvals in China position it as a key player in the global oncology market, with significant potential for growth through international regulatory approvals and commercialization.
What we're watching
- Clinical Trial Progress
- How the outcomes of the POLARIS and GLORA trials will impact Ascentage Pharma's regulatory approvals and commercialization strategy.
- Investor Sentiment
- Whether the upcoming investor conferences will bolster confidence in Ascentage Pharma's pipeline and partnerships.
- Global Expansion
- The pace at which Ascentage Pharma can expand its commercial presence beyond China, particularly in the U.S. and Europe.
Related topics